$1.55
+0.05 (+3.33%)
Open$1.48
Previous Close$1.50
Day High$1.60
Day Low$1.43
52W High$2.35
52W Low$0.77
Volume—
Avg Volume292.2K
Market Cap23.89M
P/E Ratio—
EPS$-0.80
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+2,001.9% upside
Current
$1.55
$1.55
Target
$32.58
$32.58
$17.80
$32.58 avg
$40.39
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 343.7K | 2.19M | 1.96M |
| Net Income | -12,037,335 | -647,190 | -493,473 |
| Profit Margin | -3,509.7% | -29.6% | -25.2% |
| EBITDA | -13,509,062 | -712,204 | -583,546 |
| Free Cash Flow | — | -781,686 | -525,232 |
| Rev Growth | — | +18.0% | +10.8% |
| Debt/Equity | 0.14 | 0.28 | 0.23 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |